PredicTx Health
Category: AI in Healthcare
AI-powered platform that analyzes CT scans to personalize chemotherapy dosing based on body composition analysis PredicTx Health was founded in 2025. The company is led by Abhijeet Waykar. Based in Melbourne, Australia. Team size: 1-10. Total funding raised: $1.6 million. Latest round: Pre-Seed. Key investors include University of Melbourne Genesis Pre-Seed Fund, Artesian, Scale Investors, Galileo Ventures, Australia's Economic Accelerator, Victorian Department of Health.
- Founded
- 2025
- Headquarters
- Melbourne, Australia
- Team size
- 1-10
- Total funding
- $1.6 million
Value proposition
Reduces chemotherapy toxicity by 20% and improves patient outcomes through personalized dosing based on CT scan body composition analysis rather than standard body surface area model
Products and solutions
AI-powered chemotherapy dosing platform, CT scan body composition analysis, Machine learning prediction model
Unique value
Uses AI to analyze CT scans for muscle, fat, bone, and tumor volume to create personalized chemotherapy doses, moving beyond the one-size-fits-all body surface area model
Target customer
Oncologists and clinicians in cancer treatment centers
Industries served
Healthcare, Oncology
Technology advantage
First platform to use body composition analysis from CT scans for chemotherapy dosing, potentially reducing severe side effects by 20% and improving treatment efficacy
How they differentiate
PredicTx differentiates by specifically focusing on body composition analysis from CT scans for chemotherapy dosing, while competitors use broader genomic and clinical data approaches
Main competitors
Onc.ai, Tempus, Predictive Oncology
Key partnerships
University of Melbourne (spin-out), Western Health, Hospitals in India (prospective studies)
Notable customers
Not publicly available
Major milestones
Secured $1.6 million in pre-seed funding, Completed prospective study with hospitals in India, Spun out from University of Melbourne and Western Health, Platform shows potential to reduce chemotherapy side effects by 20%
Growth metrics
Not publicly available
Market positioning
Early-stage specialized tool for oncologists, competing against more established precision oncology platforms
Geographic focus
Australian market initially, expanding to India, Middle East, and Asia-Pacific regions
Patents and IP
Not publicly available
About Abhijeet Waykar
15+ years building digital health and AI solutions at Siemens, Philips, and 4DMedical. Founded and scaled Lenia Health across three countries.
Official website: https://predictx.health/